Status:
COMPLETED
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
Lead Sponsor:
CardioDx
Conditions:
Angina Pectoris
Coronary Artery Disease
Eligibility:
All Genders
21-99 years
Brief Summary
To investigate whether the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay changes the diagnostic testing pattern in patients referred to a cardiologist for the evaluation of ches...
Detailed Description
A prospective cohort of 88 subjects receiving the Corus CAD (Age/Sex/Gene Expression score - ASGES) assay were compared to a retrospective cohort of 83 subjects that did not receive the assay.
Eligibility Criteria
Inclusion
- Stable chest pain, typical or atypical angina or anginal equivalent
- The patient has signed the appropriate Institutional Review Board approved Informed Consent Form.
Exclusion
- History of myocardial infarction
- Current myocardial infarct (MI) or acute coronary syndrome
- Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms
- Any previous coronary revascularization
- Any individuals with:
- Diabetes
- Suspected unstable angina
- Systemic infections
- Systemic inflammatory conditions
- Any individuals currently taking:
- Steroids
- Immunosuppressive agents
- Chemotherapeutic agents
- Recipient of any organ transplant
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT01251302
Start Date
November 1 2010
End Date
June 1 2012
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232